Consolidated Standards of Reporting Trials

Consolidated Standards of Reporting Trials
Name	Consolidated Standards of Reporting Trials
Abbreviation	CONSORT
Established	1996
Purpose	Reporting randomized controlled trials
Website	CONSORT Group

Consolidated Standards of Reporting Trials is an evidence-based, minimum set of recommendations for reporting randomized controlled trials used by researchers, journals, and regulators to improve transparency and reproducibility. It provides a structured checklist and a flow diagram to standardize the presentation of trial design, conduct, analysis, and interpretation in published reports. Major medical journals, professional societies, regulatory agencies, and academic institutions endorse its use to raise the quality of trial reports submitted for peer review.

Overview

The initiative articulates a standardized framework for reporting randomized trials endorsed by organizations such as New England Journal of Medicine, The Lancet, Journal of the American Medical Association, BMJ Group, and Cochrane Collaboration, promoting consistency across submissions from investigators affiliated with Harvard University, University of Oxford, Johns Hopkins University, Stanford University, and University of Cambridge. The checklist and flow diagram align with methodological guidance from International Committee of Medical Journal Editors, CONSORT Group, World Health Organization, Food and Drug Administration, and European Medicines Agency, facilitating evaluation by reviewers at institutions like National Institutes of Health, Wellcome Trust, Medical Research Council, and National Health Service. Adoption intersects editorial policies of publishers such as Elsevier, Springer Nature, Wiley-Blackwell, Taylor & Francis Group, and SAGE Publications.

History and Development

The standards originated from collaborative meetings involving statisticians and editors from British Medical Journal, Lancet Group, JAMA Network, and representatives of academic centers including London School of Hygiene & Tropical Medicine, University College London, Yale University, and University of Toronto. Early contributors included methodologists connected to Cochrane Collaboration, regulatory scientists from FDA, and funders like Wellcome Trust and NIH, with iterations published in journals such as BMJ, The Lancet, and Annals of Internal Medicine. The initiative built on earlier reporting efforts linked to figures from Cochrane and institutions like Oxford Centre for Evidence-Based Medicine and was shaped by discourse at conferences held by American Statistical Association, Society for Clinical Trials, European Society for Clinical Investigation, and International Society for Clinical Biostatistics.

CONSORT Statement and Checklist

The core statement comprises a 25-item checklist and a flow diagram that specify required elements for titles, abstracts, methods, results, and discussion, reflecting standards advocated by editors at New England Journal of Medicine, BMJ Group, JAMA Network, and The Lancet. The checklist covers trial registration practices promoted by ClinicalTrials.gov, European Clinical Trials Database, and WHO International Clinical Trials Registry Platform, and aligns with ethical oversight from Institutional Review Board processes at universities like Harvard, Oxford, and Cambridge. Methods items reference statistical reporting practices consistent with guidance from American Statistical Association, International Committee of Medical Journal Editors, and funders such as Wellcome Trust and NIH. The flow diagram depicts participant flow from enrollment to analysis, a concept familiar to investigators at Mayo Clinic, Cleveland Clinic, Mount Sinai Health System, and Massachusetts General Hospital.

Extensions and Adaptations

Extensions broaden applicability to specific trial designs and modalities, including extensions for cluster randomized trials influenced by researchers at London School of Hygiene & Tropical Medicine and McMaster University, non-inferiority and equivalence trials discussed at European Medicines Agency workshops, pragmatic trials connected to NIHR, and herbal medicine trials with contributors from Beijing University of Chinese Medicine. Additional extensions address reporting for pilot and feasibility studies linked to National Institutes of Health, adaptive designs examined at meetings of International Society for Clinical Biostatistics, patient-reported outcomes connected to PROMIS initiatives, and economic evaluations interfacing with the National Institute for Health and Care Excellence. Specialized extensions and elaborations have emerged from collaborations with organizations such as CONSORT Group, EQUATOR Network, Cochrane Collaboration, and editorial boards of BMJ, JAMA, and The Lancet.

Impact and Evidence of Use

Empirical evaluations by research groups at University of Oxford, University of Bristol, McMaster University, and University of Toronto indicate improved completeness of reporting in journals endorsing the standards, with systematic reviews published in venues like BMJ, The Lancet, and Cochrane Database of Systematic Reviews documenting enhanced reporting of randomization, allocation concealment, and flow of participants. Meta-research from teams at Stanford University, Harvard School of Public Health, Yale School of Medicine, and University College London assesses adherence trends and the effect on risk-of-bias assessments used by reviewers at Cochrane Collaboration, National Institute for Health and Care Excellence, and health technology assessment agencies. Policy changes at publishers including Elsevier, Springer Nature, and Wiley reflect consensus recommendations promoted by ICMJE and EQUATOR Network.

Implementation and Reporting Practices

Journal endorsement strategies implemented by editorial offices at BMJ, JAMA Network, The Lancet, and PLOS Medicine include mandatory checklists at submission, peer-review guidance for handling CONSORT items, and integration into editorial workflows at publishers such as Springer Nature and Elsevier. Training programs at institutions like Johns Hopkins Bloomberg School of Public Health, London School of Hygiene & Tropical Medicine, Harvard T.H. Chan School of Public Health, and Karolinska Institutet teach investigators and trial coordinators how to complete CONSORT-compliant manuscripts. Trial registries including ClinicalTrials.gov and ISRCTN encourage linkage between registry records and CONSORT-compliant reports to facilitate transparency for regulators such as FDA and agencies like EMA.

Criticisms and Limitations

Critiques from methodologists affiliated with McMaster University, University of Bristol, University of Oxford, and Stanford University note variable adherence, limited enforcement by some journals including smaller specialty titles, and difficulties adapting checklist items for complex designs encountered at institutions like NIHR and research networks such as CTSU; systematic reviewers at Cochrane Collaboration and policy analysts at NICE highlight persistent gaps in reporting of harms, subgroup analyses, and deviations from protocols. Debates in editorials in BMJ, The Lancet, and JAMA and discussions at conferences hosted by American Public Health Association and Society for Clinical Trials consider whether prescriptive checklists might constrain novel methodological reporting or fail to capture contextual nuances of trials conducted by groups at NIH, Wellcome Trust, and other funders.

Category:Reporting guidelines